CiteFacts · FDA Drug Shortages · FDA source
Methotrexate Sodium Injection
Status
FDA currently lists this ingredient in shortage.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| Accord Healthcare Inc. | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30) | Available | 08/17/2026 |
| Accord Healthcare Inc. | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35) | Available | 08/17/2026 |
| Fresenius Kabi USA, LLC | Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10) | Available | 08/04/2026 |
| Hikma Pharmaceuticals USA, Inc. | Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01) | Unavailable | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10) | Available | 08/13/2026 |
| Hospira, Inc., a Pfizer Company | Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38) | Available | 08/07/2026 |
| Teva Pharmaceuticals USA, Inc. | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01) | Unavailable | 08/17/2026 |
| Teva Pharmaceuticals USA, Inc. | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01) | Unavailable | 08/17/2026 |
| Teva Pharmaceuticals USA, Inc. | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01) | Unavailable | 08/17/2026 |
Source facts
Grouped generic ingredient: Methotrexate Sodium Injection · 14 package records · Latest FDA row update: 08/17/2026
Therapeutic categories: Oncology, Rheumatology
Dosage forms: Injection
Routes: INTRA-ARTERIAL, INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS, SUBCUTANEOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.